department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Ojjaara · pharmadog

pharmadog
drugs
Ojjaara

drug

patient view →

momelotinib dihydrochloride

Marketedupdated 2mo ago

by GlaxoSmithKline LLC

Approved

community read0 votes

all catalysts(4)

approval · 4

OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) — FDA approval

momelotinib dihydrochloride

OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) — FDA approval

momelotinib dihydrochloride

OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) — FDA approval

momelotinib dihydrochloride

OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) — FDA approval

momelotinib dihydrochloride

News(0)

no news has mentioned this drug yet

brand

Ojjaara

generic

momelotinib dihydrochloride

indication

Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 15, 2028

~2.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (15)

Dec 2, 2040method-of-use (U-3928)US 11963962
Dec 2, 2040method-of-use (U-3928)US 11963962
Dec 2, 2040method-of-use (U-3928)US 11963962
Aug 21, 2039method-of-use (U-4441)US 12576089
Aug 21, 2039method-of-use (U-4441)US 12576089
Aug 21, 2039method-of-use (U-4441)US 12576089
Jun 11, 2035method-of-use (U-1201)US 9809559
Jun 11, 2035method-of-use (U-1201)US 9809559
Jun 11, 2035method-of-use (U-1201)US 9809559
Jun 11, 2035compositionUS RE48285
Jun 11, 2035compositionUS RE48285
Jun 11, 2035compositionUS RE48285
Jan 3, 2030compositionUS 84869413.5y
Jan 3, 2030compositionUS 84869413.5y
Jan 3, 2030compositionUS 84869413.5y

FDA exclusivities (6)

Sep 15, 2030ODE-441Orphan Drug (7y)4.2y
Sep 15, 2030ODE-441Orphan Drug (7y)4.2y
Sep 15, 2030ODE-441Orphan Drug (7y)4.2y
Sep 15, 2028NCENew Chemical Entity (5y)2.2y
Sep 15, 2028NCENew Chemical Entity (5y)2.2y
Sep 15, 2028NCENew Chemical Entity (5y)2.2y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

drugOJJAARA16 co-mentions · 4 sources
tagApproval16 co-mentions · 4 sources
tagSmall Molecule8 co-mentions · 4 sources